Siddhartha (Sid) Jain is a biopharmaceutical leader with nearly two decades of experience in CMC development, MSAT, Process Sciences and Quality roles. Currently, he is the President of Shoolin Management Company – a life sciences CMC consulting firm.

Sid has contributed to the CMC development and manufacturing of several commercial biologics drugs (including Orencia, Eylea, Praluent and Dupixent) and clinical molecules (one of the first AI-designed monoclonal antibodies). Throughout his career, he introduced several new capabilities, established best practices and published articles related to the biopharmaceutical industry. Sid has Ph.D. in Biological Engineering from Massachusetts Institute of Technology and B.Tech and M.Tech in Biochemical Engineering & Biotechnology from Indian Institute of Technology.